

Press release

Genomtec's Supervisory Board appointed Leroy Huntley to the Company's Management Board

Wrocław, July 31, 2025 – Genomtec S.A., a molecular diagnostics company based in Wrocław (WSE ticker: GMT), announced the appointment of Mr. Leroy Huntley to the Company's Management Board on July 30, 2025, with effect from August 1, 2025. Leroy Huntley serves as Chief Technology Officer (CTO) at Genomtec and has been associated with the Company since 2022. His appointment strengthens the Management Board's competences at a key moment for the Company – the ongoing M&A process.

Leroy Huntley has over 40 years of experience in both device design and manufacturing. He has spent nearly two decades of his professional career in the medical device sector, developing and implementing products into production. He has spent the vast majority of his career in senior management positions, including engineering directors across a range of industries: medical, safety, device component manufacturing, and more. While managing his own successful design and manufacturing company in the instrumentation sector, he has also advised the boards of technology companies. His substantive input was crucial during the design phase of the company's flagship product, the Genomtec ID system.

Miron Tokarski, President of the Management Board of Genomtec, comments on the appointment of Leroy Huntley to the Management Board:

"Leroy has significantly contributed to the development of our technology and has international experience in advising technology companies. Therefore, his appointment is an important reinforcement of our management structure at a time when we are actively engaging in discussions with potential strategic partners and investors. I am confident that our joint work on the Board will be beneficial to achieving Genomtec's strategic development goals."

Leroy Huntley comments on his nomination:

"I'm delighted to be able to strengthen the Genomtec Board with my experience. Genomtec is an incredibly exciting place, with a great team achieving significant progress on their projects. I believe my extensive technical and business experience will strengthen the Board and help lead the company towards achieving its short- and long-term goals."

About Genomtec:

Genomtec is a MedTech company specializing in developing advanced technologies in the field of genetic diagnostics. The company's flagship project is the Genomtec ID mobile diagnostic system. The system allows for quick and precise molecular analysis outside the laboratory environment without the need for qualified laboratory personnel. The solution utilizes microfluidic technology and proprietary, patented isothermal technology. SNAAT® Genomtec's technology is protected by 12 patents in Europe, the US, and Japan, among others, and the company has 35 patent applications pending.

The company has EU CE-IVD certification for the Genomtec ID RP5-PLEX diagnostic panel, which simultaneously detects the presence of the most common respiratory tract infections

The company is headquartered in Wrocław. Genomtec also has a presence in the UK, where an office and part of its international research and engineering team are located.

More information is available on the company's website: www.genomtec.com

Media contact:

Michał Wierzchowski

Tel.: +48 531 613 067

michal.wierzchowski@ccgroup.pl

Contact for investors:

Agata Dzieciołowska

Tel.: +48 606 205 119

agata.dzieciolowska@ccgroup.pl